Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 8/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.82 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.73 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25046266 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL29432374 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL29432352 | 0.90 | CHRM4 (1.00) | CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL29432024 | 0.90 | CHRM4 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL23478444 | 0.90 | CHRM4 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL23502265 | 0.90 | CHRM4 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL18825813 | 0.89 | CHRM4 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL29432209 | 0.89 | CHRM4 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL18826028 | 0.87 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL29432016 | 0.87 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3371164-B1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210338653-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2021-11-04 | — | — | US | disclosed |
| CN-108349936-B | Compounds as muscarinic receptor 4 antagonists | 纽罗克里生物科学有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20180325887-A1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2018-11-15 | — | — | US | disclosed |
| EP-3371164-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017079641-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | CHRM2, CHRM4, CHRM1 | CHRM2 1/4885CHRM4 2/4885CHRM5 4/4885 |
| US-20180325887-A1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | CHRM1, CHRM2, CHRM4 | CHRM2 2/4885CHRM4 3/4885CHRM5 4/4885 |
| US-20210338653-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | CHRM2, CHRM1, CHRM4 | CHRM2 1/4885CHRM4 3/4885CHRM5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.